Company Overview and News

0
SANOFI VOLTOOIT HAAR ACQUISITIE VAN ABLYNX NA HET VERSTRIJKEN VAN DE SQUEEZE-OUT PROCEDURE

2018-06-19 globenewswire
PARIJS, Frankrijk en GENT, België - 19 juni 2018 - Sanofi (Euronext: SAN; NYSE: SNY) en Ablynx kondigen vandaag aan dat Sanofi nu alle uitstaande aandelen (met inbegrip van aandelen vertegenwoordigd door American Depositary Shares ("ADSs")), warrants en converteerbare obligaties (samen, de "Effecten") van Ablynx NV ("Ablynx") heeft verworven na het verstrijken van de Squeeze-out procedure.
MKGAF MKGAY ABYLY SNY ABLX ABLYF

0
SANOFI COMPLETES ITS ACQUITISION OF ABLYNX FOLLOWING THE EXPIRATION OF THE SQUEEZE-OUT PROCEDURE

2018-06-19 globenewswire
PARIS, France and GHENT, Belgium - June 19, 2018 - Sanofi (Euronext: SAN; NYSE: SNY) and Ablynx announced today that Sanofi has now acquired all outstanding shares (including shares represented by American Depositary Shares ("ADSs")), warrants and convertible bonds (together, the "Securities") of Ablynx NV ("Ablynx") following the expiration of the Squeeze-out procedure.
MKGAF MKGAY ABYLY SNY ABLX ABLYF

0
ECA2018-104 - Information Regarding the Squeeze-Out and Tender Offer for Ablynx NV (ABLX)

2018-06-11 nasdaqtrader
The squeeze-out period following the expiration of the tender offer by Sanofi to acquire all of the outstanding shares and by representation, the American Depositary Shares of Ablynx NV (ABLX), is expected to be completed on Tuesday, June 12, 2018. If completed, the squeeze-out period will allow for the completion of the acquisition of Ablynx NV on June 12, 2018. The details are as follows:
ABYLY ABLX ABLYF

0
OPENBAARMAKING IN OVEREENSTEMMING MET ARTIKEL 14 VAN DE BELGISCHE WET VAN 2 MEI 2007 BETREFFENDE DE OPENBAARMAKING VAN BELANGRIJKE DEELNEMINGEN (DE "TRANSPARANTIEWET")

2018-05-28 globenewswire
GENT, België, 28 mei 2018 - Ablynx [Euronext Brussels en Nasdaq: ABLX] maakte vandaag bekend, in overeenstemming met artikel 14 van de Belgische wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen in emittenten van wie aandelen zijn toegelaten tot verhandeling op een gereglementeerde markt (de "Transparantiewet"), dat zij op 24 mei 2018 een kennisgeving van deelneming heeft ontvangen van Sanofi S.
MKGAF MKGAY ABYLY ABLX ABLYF

0
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

2018-05-28 globenewswire
GHENT, Belgium, 28 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Sanofi S.A. on 24 May 2018.
MKGAF MKGAY ABYLY ABLX ABLYF

0
OPENBAARMAKING IN OVEREENSTEMMING MET ARTIKEL 14 VAN DE BELGISCHE WET VAN 2 MEI 2007 BETREFFENDE DE OPENBAARMAKING VAN BELANGRIJKE DEELNEMINGEN (DE "TRANSPARANTIEWET")

2018-05-28 globenewswire
GENT, België, 28 mei 2018 - Ablynx [Euronext Brussels en Nasdaq: ABLX] maakte vandaag bekend, in overeenstemming met artikel 14 van de Belgische wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen in emittenten van wie aandelen zijn toegelaten tot verhandeling op een gereglementeerde markt (de "Transparantiewet"), dat zij kennisgevingen van deelneming heeft ontvangen van Farallon Capital Management, LLC; Marshall Wace LLP; Van Herk Investments B.
MKGAF MKGAY ABYLY ABLX ABLYF

0
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

2018-05-28 globenewswire
GHENT, Belgium, 28 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received notifications of shareholdings from Farallon Capital Management, LLC; Marshall Wace LLP; Van Herk Investments B.
MKGAF MKGAY ABYLY ABLX ABLYF

0
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

2018-05-21 globenewswire
GHENT, Belgium, 21 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from BlackRock, Inc. on 16 May 2018.
MKGAF MKGAY ABYLY ABLX ABLYF

0
OPENBAARMAKING IN OVEREENSTEMMING MET ARTIKEL 14 VAN DE BELGISCHE WET VAN 2 MEI 2007 BETREFFENDE DE OPENBAARMAKING VAN BELANGRIJKE DEELNEMINGEN (DE "TRANSPARANTIEWET")

2018-05-21 globenewswire
GENT, België, 21 mei 2018 - Ablynx [Euronext Brussels en Nasdaq: ABLX] maakte vandaag bekend, in overeenstemming met artikel 14 van de Belgische wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen in emittenten van wie aandelen zijn toegelaten tot verhandeling op een gereglementeerde markt (de "Transparantiewet"), dat zij op 16 mei 2018 een kennisgeving van deelneming heeft ontvangen van BlackRock, Inc.
MKGAF MKGAY ABYLY ABLX ABLYF

0
OPENBAARMAKING IN OVEREENSTEMMING MET ARTIKEL 14 VAN DE BELGISCHE WET VAN 2 MEI 2007 BETREFFENDE DE OPENBAARMAKING VAN BELANGRIJKE DEELNEMINGEN (DE "TRANSPARANTIEWET")

2018-05-11 globenewswire
GENT, België, 11 mei 2018 - Ablynx [Euronext Brussels en Nasdaq: ABLX] maakte vandaag bekend, in overeenstemming met artikel 14 van de Belgische wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen in emittenten van wie aandelen zijn toegelaten tot verhandeling op een gereglementeerde markt (de "Transparantiewet"), dat zij op 8 mei 2018 een kennisgeving van deelneming heeft ontvangen van BlackRock, Inc.
MKGAF MKGAY ABYLY ABLX ABLYF

0
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

2018-05-11 globenewswire
GHENT, Belgium, 11 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from BlackRock, Inc. on 8 May 2018.
MKGAF MKGAY ABYLY ABLX ABLYF

0
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

2018-05-08 globenewswire
GHENT, Belgium, 8 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received two notification of shareholdings from BlackRock, Inc. on 3 and 7 May 2018.
MKGAF MKGAY ABYLY ABLX ABLYF

0
OPENBAARMAKING IN OVEREENSTEMMING MET ARTIKEL 14 VAN DE BELGISCHE WET VAN 2 MEI 2007 BETREFFENDE DE OPENBAARMAKING VAN BELANGRIJKE DEELNEMINGEN (DE "TRANSPARANTIEWET")

2018-05-08 globenewswire
GENT, België, 8 mei 2018 - Ablynx [Euronext Brussels en Nasdaq: ABLX] maakte vandaag bekend, in overeenstemming met artikel 14 van de Belgische wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen in emittenten van wie aandelen zijn toegelaten tot verhandeling op een gereglementeerde markt (de "Transparantiewet"), dat zij op 3 mei 2018 twee kennisgevingen van deelneming heeft ontvangen van BlackRock, Inc.
MKGAF MKGAY ABYLY ABLX ABLYF

2
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

2018-05-03 globenewswire
GHENT, Belgium, 3 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received two notifications of shareholdings from UBS Group AG on 30 April 2018.
MKGAF MKGAY UBS UBS.PRDCL ABYLY ULSGF ABLX ABLYF

2
OPENBAARMAKING IN OVEREENSTEMMING MET ARTIKEL 14 VAN DE BELGISCHE WET VAN 2 MEI 2007 BETREFFENDE DE OPENBAARMAKING VAN BELANGRIJKE DEELNEMINGEN (DE "TRANSPARANTIEWET")

2018-05-03 globenewswire
GENT, België, 3 mei 2018 - Ablynx [Euronext Brussels en Nasdaq: ABLX] maakte vandaag bekend, in overeenstemming met artikel 14 van de Belgische wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen in emittenten van wie aandelen zijn toegelaten tot verhandeling op een gereglementeerde markt (de "Transparantiewet"), dat zij op 30 april 2018 twee kennisgevingen van deelneming heeft ontvangen van UBS Group AG.
MKGAF MKGAY UBS UBS.PRDCL ABYLY ULSGF ABLX ABLYF

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...